These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12939737)

  • 1. Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects.
    Schernthaner G
    Metabolism; 2003 Aug; 52(8 Suppl 1):29-34. PubMed ID: 12939737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Medication of the month. Gliclazide modified release (Uni Diamicron)].
    Scheen AJ
    Rev Med Liege; 2003 Oct; 58(10):641-5. PubMed ID: 14677526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gliclazide modified release.
    McGavin JK; Perry CM; Goa KL
    Drugs; 2002; 62(9):1357-64; discussion 1365-6. PubMed ID: 12076188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.
    Harrower A
    Metabolism; 2000 Oct; 49(10 Suppl 2):7-11. PubMed ID: 11078469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.
    Lu CH; Chang CC; Chuang LM; Wang CY; Jiang YD; Wu HP
    Diabetes Obes Metab; 2006 Mar; 8(2):184-91. PubMed ID: 16448522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care.
    Ramachandran A
    Diabetes Res Clin Pract; 2003 Oct; 62(1):63-4. PubMed ID: 14581160
    [No Abstract]   [Full Text] [Related]  

  • 7. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.
    Guillausseau PJ; Greb W
    Diabetes Metab; 2001 Apr; 27(2 Pt 1):133-7. PubMed ID: 11353879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliclazide modified release.
    Rambiritch V; Naidoo P
    Drugs; 2005; 65(10):1449-50. PubMed ID: 15977973
    [No Abstract]   [Full Text] [Related]  

  • 9. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.
    Frey N; Laveille C; Paraire M; Francillard M; Holford NH; Jochemsen R
    Br J Clin Pharmacol; 2003 Feb; 55(2):147-57. PubMed ID: 12580986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiologic Surveillance of Glycemic Response to a Scored, Breakable, Extended Release, Fixed Dose Combination of Gliclazide and Metformin in Persons with Type 2 Diabetes.
    Kalra S; Das AK
    J Assoc Physicians India; 2017 Jun; 65(6):38-41. PubMed ID: 28782312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation.
    Leiter LA; Shestakova MV; Trubitsyna NP; Piletič M; Satman I
    Diabetes Res Clin Pract; 2016 Feb; 112():50-56. PubMed ID: 26653612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes.
    Drouin P; Standl E;
    Diabetes Obes Metab; 2004 Nov; 6(6):414-21. PubMed ID: 15479217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.
    Delrat P; Paraire M; Jochemsen R
    Biopharm Drug Dispos; 2002 May; 23(4):151-7. PubMed ID: 12015789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model.
    Panda BP; Krishnamoorthy R; Bhattamisra SK; Shivashekaregowda NKH; Seng LB; Patnaik S
    Sci Rep; 2019 Nov; 9(1):17331. PubMed ID: 31758056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gliclazide: review of metabolic and vascular action].
    Alberti KG
    Diabete Metab; 1994 Nov; 20(3 Pt 2):341-8. PubMed ID: 7828778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical availability of gliclazide from selected matrix formulation tablets.
    Hermann TW; Dobrucki R; Piechocki S; Resztak M; Reh R
    Med Sci Monit; 2005 Jun; 11(6):BR181-188. PubMed ID: 15917713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A multicenter clinic study of slow-release-gliclazide in type 2 diabetes mellitus].
    Jia WP; Ning G; Gao X; Yan L; Yang HZ; Li M; Hong J; Lu ZQ; Cheng H; Qi YQ; Li ZW; Xiang KS
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(37):2636-9. PubMed ID: 16321325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
    Kardas P
    Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast.
    Zargar AH; Siraj M; Jawa AA; Hasan M; Mahtab H
    Int J Clin Pract; 2010 Jul; 64(8):1090-4. PubMed ID: 20455956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of two hydrophobic polymers on the release of gliclazide from their matrix tablets.
    Hussain T; Saeed T; Mumtaz AM; Javaid Z; Abbas K; Awais A; Idrees HA
    Acta Pol Pharm; 2013; 70(4):749-57. PubMed ID: 23923399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.